The aim of this study was to evaluate the effect of obesity on renal functions and the possible relationship between TGF-β1 and obesity in hypertensive patients. Seventy newly diagnosed, hypertensive patients (male/female 36/34, aged 45.0 ± 8.0 years) and 30 (male/female 17/13, aged 41.8 ± 7.7 years) normotensive controls were included. Patients in both groups were analyzed for serum levels of glucose, creatinine, uric acid, lipids, and TGF-β1. A 24-hour urine sample was also obtained; creatinine clearance rate and urinary albumin excretion (UEA) were investigated. TGF-β1 levels were significantly higher (40.7 ± 13.6 versus 34.2 ± 12.1 pg/mL, P = 0.02), and creatinine clearance was significantly lower in patients compared with controls (98.9 ± 25.5 versus 124.5 ± 23.1 mL/min. per. 1.73 m 2 , P = 0.001). Serum TGF-β1 levels (45.2 ± 14 versis 38.0 ± 12.8 pg/mL, P = 0.03), creatinine clearance rates (109.8 29.9 versus 93.0 ± 20.8 mL/min. per. 1.73 m 2 , P = 0.001), and urinary albumin excretion (55.7 ± 62.0 versus 12.7 ± 12.6 mg/24 h, P = 0.002) were higher in obese hypertensive patients than in nonobese patients. In hypertensive patients, TGF-β1 levels correlated with body mass index (r = 0.296, P = 0.01) and creatinine clearance (r = 0.238, P = 0.04). The results suggest that increased body mass index is associated with increased creatinine clearance, urinary albumin excretion, and TGF-β1 levels in essential hypertension. In addition, TGF-β1 is positively correlated with body mass index and creatinine clearance in patients with essential hypertension. (Int Heart J 2007; 48: 733-741) 
No definitive data exist for determining which patients with mild to moderate essential hypertension will develop renal insufficiency. In previous studies, black race, advanced age, and male sex are some of the risk factors for developing renal failure. 2, 3) Transforming growth factor beta (TGF-β1) is a cytokine that has been shown to be a factor in cell growth, differentiation, and matrix production. It is synthesized from monocytes and endothelial and vascular smooth muscle cells, and it has been shown to contribute to the pathogenesis of cancer and fibrotic diseases. 4 ) Levels of TGF-β1 also have been demonstrated as being greater in hypertensive patients than in normotensive patients. In addition, increased TGF-β1 production has been correlated with hypertensive end-organ damage. [5] [6] [7] Obesity is an independent risk factor for essential hypertension and cardiovascular diseases. There is a strong relationship between body mass index (BMI) and blood pressure. In addition, obesity is a risk factor for progression of renal dysfunction in patients with chronic renal dysfunction. Moreover, evidence suggests that obesity may cause disturbances in renal functions. Obesity leads to glomerulosclerosis via renal vasodilatation and increases in glomerular filtration and hydrostatic pressure. 8, 9) Porreca and coworkers have reported that TGF-β1 levels are independently associated with obesity in hypertensive patients. 10) The aim of this study was to evaluate the effect of obesity on renal functions and the possible relationship between TGF-β1 and obesity in hypertensive patients.
METHODS
The study population consisted of 70 untreated, newly diagnosed patients with mild to moderate essential hypertension (36 men and 34 women, aged 45.0 ± 8.0 years) and 30 normotensive controls (17 men and 13 women, aged 41.8 ± 7.7 years). Informed consent was obtained from each participant, and the study protocol was conducted in accordance with the Declaration of Helsinki. Permission for this cross-sectional study was granted by the Institutional Review Board of Baskent University in Ankara, Turkey.
Persons with conditions that might affect serum TGF-β1 levels (eg, diabetes mellitus, malignancy, acute or chronic liver diseases, coronary artery diseases, collagen vascular diseases, inflammatory states, and secondary hypertension) were excluded.
Patients and controls were further subdivided into two groups according to BMI as obese and nonobese. A BMI lower than 30 kg/m 2 was considered as nonobese, and a BMI greater than 30 kg/m 2 was accepted as obese. Blood pressure measurements: Clinic blood pressure was measured by a mer-Vol 48 No 6 cury sphygmomanometer after the patient had been in a sitting position for 5 minutes. Blood pressure measurements were performed by a physician. For each subject, we recorded the average of 3 readings obtained within 5 minutes of each other. Hypertension was defined as systolic BP ≥ 140 mmHg and diastolic BP ≥ 90 mmHg, as recommended in the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.
11) Mean arterial pressure (MAP) was calculated from the equation (SBP + 2DBP)/3, in which SBP and DBP represent systolic and diastolic blood pressures, respectively. Pulse pressure was the arithmetic difference between averaged SBP and DBP values. Data collection: A fasting blood sample was collected from patients and controls and analyzed for serum levels of glucose, creatinine, uric acid, total cholesterol, low-density lipoprotein, high-density lipoprotein, and triglycerides. A 24-hour urine sample was also obtained; creatinine clearance rate and urinary albumin excretion (UEA) were investigated. Urinary albumin excretion was detected in a 24-hour urine sample by radioimmunoassay. Microalbuminuria was defined as UAE ≥ 30 mg/24 h and < 300 mg/24 h.
Peripheral venous blood was obtained from both hypertensive patients and normotensive controls and sera were isolated and stored at -70°C until assayed for TGF-β1. The concentration of the biologically active form of TGF-β1 protein was measured using a solid-phase TGF-β1 sandwich ELISA (Qantikine human TGF-β1 ELISA, R & D Systems, Inc., Minneapolis MN, USA). The minimum detectable dose of TGF-β1 is less than 7 pg/mL. Statistical analyses: Statistical analyses were performed using SPSS software (Statistical Package for the Social Sciences, version 10.0, SSPS Inc., Chicago, Ill, USA). Continuous variables are expressed as the mean ± SD. The TGF-β1 values are expressed as the median (interquartile range). Parametric between-group differences were evaluated using the Student t test. The chi-square test was used to compare categorical values. The Pearson correlation coefficient was used to express correlations between variables. P values < 0.05 were accepted as statistically significant.
RESULTS
The clinical, laboratory, and demographic data of the 70 patients with essential hypertension and the 30 healthy, normotensive controls are shown in Table I . There were no significant differences in age or gender between the hypertensive and normotensive groups. Mean artery pressure, pulse pressure, waist-to-hip ratio, and BMI, serum creatinine, uric acid, and triglyceride levels were significantly higher in the hypertensive patients than in the normotensive individuals. Creatinine clearances were significantly lower in the hypertensive patients compared with the normotensives controls.
As shown in the Figure, TGF-β1 levels were higher in patients with hypertension than they were in the normotensive controls (42 pg/mL [interquartile range: 34-48] versus 36 pg/mL [interquartile range: 26-42], P = 0.01).
In the control group, BMI was lower than 30 kg/m 2 in 12 individuals and greater than 30 kg/m 2 in 18 individuals. Age, sex, mean systolic and diastolic blood pressures, biochemistry data, and TGF-β1 levels were similar between obese and nonobese persons in the normotensive control group.
With regard to BMI, 44 patients with hypertension were obese and 26 were nonobese. Waist-to-hip ratio, serum uric acid levels, HDL-C levels, triglyceride levels, and TGF-β1 levels were higher in obese hypertensive patients than they were in patients in the nonobese group. In addition, creatinine clearance levels and UAE were higher in obese patients with hypertension than they were in nonobese patients (Table II) . In hypertensive patients, serum TGF-β1 levels correlated with BMI (r = 0.296, P = 0.01) and creatinine clearance rates (r = 0.238, P = 0.04).
DISCUSSION
Essential hypertension is often associated with various metabolic abnormities including dyslipidemia, elevated glucose levels, insulin resistance, and abdominal obesity, which are the main features of the recently characterized metabolic syndrome. 12) Consistent with previous studies, the current study also demonstrated that BMI, waist-to-hip ratio, and triglyceride levels were significantly higher in patients with essential hypertension than they were in normotensive individuals.
The risk of hypertension-induced renal damage remains controversial in patients with essential hypertension in the absence of malignant nephrosclerosis. Hypertensive renal damage has been defined as a beginning or progression of renal damage caused by a systemic blood pressure load. 13) Most patients with newly diagnosed essential hypertension will have a relatively normal or slightly depressed glomerular filtration rate, a reduced renal blood flow, and elevated renal vascular resistance. Despite relatively normal renal functions, afferent arteriolosclerosis may be seen on renal biopsy. 14) In our study, hypertensive patients had significantly lower creatinine clearance levels than did normotensive individuals. This finding supports the hypothesis that essential hypertension affects the glomerular filtration rate negatively.
The role of TGF-β1 levels in the development of hypertension and renal disease has been reported in salt-sensitive rats. 15) In addition, overproduction of TGF-β1 protein has been reported in the myocardial tissue of hypertensive patients.
16) The role of the TGF-β1 level on the pathogenesis of essential hypertension has been associated with increased renin secretion from the juxtaglomerular apparatus, the regulation of angiotensin II expression, 17) and stimulation of endothelin expression in the vascular endothelium. 18) In accord with previous findings, our data reveal that TGF-β1 levels are higher in patients with essential hypertension compared with normotensive individuals.
Obesity is often associated with various comorbid conditions including hypertension, diabetes, dyslipidemia, atherosclerosis, and chronic renal failure. 19, 20) It has been suggested that obesity is a risk factor for the nephrotic syndrome due to focal segmental glomerulonephritis and deterioration of renal functioning. 21, 22) The effects of obesity on renal functions are multifactorial and include increases in renal blood flow, 23) glomerular filtration rate, 24) and systemic hypertension due to increased renal tubular sodium retention 25) and proteinuria. 26) Consistent with previous studies, our obese hypertensive patients had signifi-Vol 48 No 6 cantly higher creatinine clearance rates and UAE than did the nonobese hypertensive patients. The greater creatinine clearance rates in obese hypertensive patients compared with nonobese patients suggest that obesity may play a deleterious role in renal functioning when combined with an increase in blood pressure. Multiple pathogenic factors affect the release of TGF-β1 from different cells. The increased shear stress of the vascular endothelium due to high blood pressure may be responsible for the increased serum TGF-β1 levels seen in essential hypertension. Some, but not all, series have reported that increased TGF-β1 is associated with increased mean arterial, systolic, and diastolic blood pressure in patients with essential hypertension. Derhasching and colleagues found no association between serum TGF-β1 levels and systolic and diastolic blood pressure in essential hypertension, and they suggested that increased TGF-β1 levels are independent from blood pressure levels. 27) Consistent with the study conducted by Derhasching, we found no association between blood pressure levels and TGF-β1 in hypertensive patients. Clinical and experimental studies have revealed that obesity is associated with enhanced expression and release of TGF-β1 from adipose tissue. 28, 29) Scaglione and coworkers have indicated that TGF-β1 levels are positively associated with obesity and UAE in patients with hypertension. 30 ) Similarly, we also have shown that TGF-β1 levels are positively correlated with BMI and creatinine clearance rates.
In conclusion, we found that an increased body mass index is associated with increased creatinine clearance, urinary albumin excretion, and TGF-β1 levels in essential hypertension. In addition, TGF-β1 is positively correlated with body mass index and creatinine clearance in patients with essential hypertension. The present results suggest that obesity may contribute to the impairment of renal dysfunction associated with increased TGF-β1 levels. However, the main limitation of our study was the small size of the patient population. Further studies with larger patient groups are needed to confirm the relationship between TGF-β1 and obesity on renal damage in essential hypertension.
